Almitas Capital LLC
Source: SEC Form 13F · as of Mar 2026Almitas Capital LLC holds 8 biotech & pharma companies tracked by BioSniper, totaling $44.5M in value as of Mar 2026 (SEC Form 13F).
Companies held
8
Total value held
$44.5M
BioSniper AIPage evidence connected
Prepared research question
What matters most for Design Therapeutics, Inc. (DSGN)—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
| Company | Shares | Value |
|---|---|---|
| DSGNDesign Therapeutics, Inc. | 1,530,335 | $16.3M |
| LYELLyell Immunopharma, Inc. | 577,807 | $11.6M |
| ALXOALX ONCOLOGY HOLDINGS INC | 3,173,834 | $6.4M |
| ANTXAN2 Therapeutics, Inc. | 1,479,129 | $5.1M |
| RLYBRallybio Corp | 191,206 | $1.7M |
| FLGTFulgent Genetics Inc. | 104,797 | $1.7M |
| ZNTLZentalis Pharmaceuticals, Inc. | 610,073 | $1.4M |
| TLPHTALPHERA, INC. | 467,152 | $349K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.